Press Releases
Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
Corbus Pharmaceuticals to Announce Third Quarter 2018 Operational and Financial Results on November 8, 2018
Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
Corbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic Fibrosis Lungs at the 2018 North American Cystic Fibrosis Conference
Corbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October
Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study
Corbus Pharmaceuticals Receives Orphan Designation for Lenabasum for the Treatment of Dermatomyositis in the European Union
Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2018 ACR Annual Meeting
Corbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference
Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update
Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis
Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference
Corbus Pharmaceuticals to Present at the JMP Securities Life Science Conference
Corbus Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018
Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors
Corbus Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations
Corbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting
Corbus Pharmaceuticals Reports 2018 First Quarter Financial Results and Provides Business Update
Corbus Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
Corbus Pharmaceuticals Reports 2017 Financial Results and Provides Clinical Update
Corbus Pharmaceuticals to Present at the Cowen & Co. 38th Annual Health Care Conference
Corbus Pharmaceuticals Announces Publication Demonstrating Lenabasum as First Drug to Stimulate Resolution of Innate Immune Responses in a Clinical Model
Corbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference
Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference
Corbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support Phase 2b Clinical Study of Lenabasum
Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint
